Brands Norvir® and Reyataz® Are To Be Dispensed Over Their Respective Generics

In some instances the multisource brand name drug is required over its generic equivalents, because the branded drug is less costly than its generic counterpart. This happens most often in cases of newly released generics. When manufacturer rebates are taken into consideration, the brand name drug has a lower net cost to the State.

Effective Friday, April 27 2018, the Maryland Medicaid Pharmacy Program (MMPP) will cover brands Norvir® tablets and Reyataz® capsules over their generic counterparts (ritonavir tablets and atazanavir capsules). Claims for these products must be submitted with DAW 6 and will be priced appropriately. Claims with any other DAW code will reject. A MDH Medwatch form will not be required.

If any problems are encountered during the on-line claim adjudication, contact Conduent’s 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if there is other primary insurance).

All Advisories are available online on MDH’s web link at: https://mmcp.health.maryland.gov/pap/Pages/Provider-Advisories.aspx